Amy DeZern, M.D.

It’s an exciting time in the field of myelodysplastic syndrome (MDS), explained Amy DeZern, M.D., associate professor of Oncology and Medicine at the Johns Hopkins University School of Medicine.

Researchers and practitioners alike are learning more about the biology of the disease, as well as the molecular mutations that come along with it. This is helping to differentiate different subtypes of MDS — it is not a heterogenous disease – which will lead to better diagnostic and prognostic accuracy, as well as paving the way for the use of targeted therapy in this space.

Videos

Learning more about MDS will lead to better diagnostics and more personalized treatments.

Amy DeZern, M.D.

It's an Exciting Time for Myelodysplastic Syndrome

Latest News